The article ‘Impacto presupuestario de los biosimilares en el Sistema Nacional en España 2020-2030’ presented by the Association in Madrid reflects the significant contribution of biosimilars such as adalimumab, infliximab, ustekinumab, rituximab, and bevacizumab to the estimated total savings. The report, developed by Manuel García Goñi, a professor at the Universidad Complutense de Madrid, projects a conservative estimate of over 4,000 million euros in savings by 2030.
The study builds on previous reports, analyzing the retrospective data from 2020 to 2023 and making projections for 2024 to 2030. It indicates that biosimilars have generated substantial savings for the Spanish National Health System, with an increasing trend from 1,070 million euros in 2020 to an estimated 4,352 million euros by 2030.
The distribution of savings among different active ingredients varied, with adalimumab, infliximab, rituximab, eritropoyena, and bevacizumab contributing significantly. The report emphasizes the growing importance of biosimilars in the healthcare sector, particularly in hospital pharmacies, where savings are more substantial compared to retail pharmacies.
Cesar Hernández, the Director General of the National Health System and Pharmacy Services, highlighted the essential role of biosimilars in Spain, emphasizing the need for a competitive market to drive innovation and efficiency. Encarna Cruz from BioSim discussed the evolving landscape of biosimilars in light of new legislation, emphasizing the importance of maintaining access to these medicines for citizens.
Joaquín Rodrigo, President of BioSim, emphasized the efficiency and cost-saving potential of biosimilars, noting their role in providing patients with access to necessary biological medications. The future of biosimilars in Spain looks promising, with continued efforts to ensure a competitive and sustainable market that fosters innovation and accessibility for all.
FUENTE
